title: [Comparison of two regimens of postoperative concurrent chemoradiotherapy in adult patients with grade III-IV cerebral gliomas].
abstract: OBJECTIVE
  To compare the therapeutic efficacy of two regimens of postoperative radiotherapy with concurrent chemotherapy using temozolomide (TMZ) and teniposide (VM-26) plus semustine (Me-CCNU) in adult patients with grade III-IV cerebral gliomas.
  
  
  METHODS
  Ninety-six adult postoperative patients with grade III-IV cerebral gliomas were randomized into two groups (n=48) to receive 60 Gy radiotherapy with concurrent TMZ treatment (TMZ-RT group) and radiotherapy with VM-26 plus Me-CCNU treatments (VM-RT group). The adverse effects of marrow depression, gastrointestinal toxicity and acute radiation-induced brain injury were observed. The immediate effect and survival outcome of the patients were compared between the two groups.
  
  
  RESULTS
  No adverse effects beyond grade III were observed in the two groups. TMZ-RT group showed a significantly lower incidence of grade I-II adverse effects than VM-RT group (P<0.05). The median survival time and 1-, 2-, and 3-year survival rates of the patients in TMZ-RT group were 28 months, 72.9%, 54.2% and 31.3%, respectively, showing significant differences from those in VM-RT group (16 months, 62.5%, 33.3% and 16.7%, respectively, P<0.05).
  
  
  CONCLUSIONS
  Radiotherapy with concurrent TMZ chemotherapy is an effective regimen with mild toxicities for treatment of adult malignant cerebral glioma.
authors.affiliation: Department of Radiation Oncology, First Affiliated Hospital of Suzhou University, Suzhou, China. zhaixiaoming_sz@163.com
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Zhai
authors.forename: Jianping
authors.initials: J
authors.lastname: Wang
authors.forename: Junning
authors.initials: J
authors.lastname: Zhang
authors.forename: Ke
authors.initials: K
authors.lastname: Gu
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D005260:Female; D005910:Glioma / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D012673:Semustine / Q000008:administration & dosage; D000077204:Temozolomide; D013713:Teniposide / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D012673:Semustine; D003606:Dacarbazine; D013713:Teniposide; D000077204:Temozolomide